Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

AbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, hepatitis C, women"s health, oncology, and neuroscience. AbbVie also offers treatments for diseases including multiple sclerosis, parkinson"s, and alzheimer"s disease.
Website: abbvie.com


  • Pretty weak financial results growth rate 0.6% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (6.4%)
  • Dividend yield for the last twelve months 3.8%
  • Free cash flow yield 0.0% (LTM)
  • Share price is 50.9% higher than minimum and 11.8% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (17.9x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $79.4 mln (-0.025% of cap.)

Key Financials (Download financials)

Ticker: ABBV
Share price, USD:  (+0.1%)160.54
year average price 153.69  


year start price 146.59 2023-05-11

min close price 132.51 2023-06-28

max close price 182.10 2024-03-28

current price 160.45 2024-05-09
Common stocks: 1 768 480 508

Dividend Yield:  3.8%
EV / LTM EBITDA: 17.9x
EV / EBITDA annualized: 14.2x
Last revenue growth (y/y):  0.7%
Last growth of EBITDA (y/y):  0.6%
Historical revenue growth:  3.4%
Historical growth of EBITDA:  9.4%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 283 912
Net Debt ($m): 55 400
EV (Enterprise Value): 339 312
EBITDA LTM ($m): 18 957
EV / LTM EBITDA: 17.9x
Price to Book: 35.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2024-05-07InvestorPlace

Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare

2024-05-07MarketBeat

AbbVie Tracking for New Highs in 2024

2024-05-06PRNewsWire

AbbVie to Present at the Bank of America Securities Healthcare Conference

2024-05-05The Motley Fool

3 Reasons to Buy AbbVie Stock on the Dip

2024-05-01Zacks Investment Research

Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock

2024-05-01CNBC

Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors

2024-04-30InvestorPlace

7 Safe Haven Stocks That Can Withstand the Market's Worst Meltdowns

2024-04-30Zacks Investment Research

AbbVie (ABBV) Could Be a Great Choice

2024-04-30InvestorPlace

Inflation-Proof Fortunes: 7 Dividend Aristocrats to Keep Your Wealth Growing

2024-04-28The Motley Fool

Better Dividend Stock: AbbVie or Johnson & Johnson?
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data